264 Chapter 9 sleep length difference, and HLA-DQB1*0602 positivity. Subdivision of these individuals based only on absolute sleep duration or presence of SOREMPs is not supported by our findings. Introduction of new clinical biomarkers such as sleep drunkenness and weekend-week sleep length difference provides necessary opportunity to develop improved diagnostic criteria for people without cataplexy. At its very best, new data-driven classification of hypersomnolence disorders with levels of certainty would result in a reproducible, holistic classification system that better identifies borderline individuals and is less susceptible to volatility in single features. Authorship contribution statement Conception and design of the study: JKG, ZZ, MSSLO, SM, RF, RK, GJL. Acquisition of data: JKG, ZZ, YD, GM, GP, RRV, JSC, KS, MP, OS, RPA, RH, AMS, BH, AW, AH, EF, MM, JB, FC, CLB, LB, FP, RF, RK, GJL. Analysis of data: JKG, ZZ, MSSLO, SM, RF, RK, GJL. Interpretation of results: JKG, ZZ, MSSLO, SM, RF, RK, GJL. Manuscript writing and revisions: JKG, ZZ, MSSLO, SM, YD, GM, GP, RRV, JSC, KS, MP, OS, RPA, RH, AMS, BH, AW, AH, EF, MM, JB, FC, CLB, LB, FP, MHS, RF, RK, GJL. Disclosure statement Financial disclosure: The EU-NN has received financial support from UCB Pharma Brussels for developing the EU-NN database. UCB Pharma Brussels has had no involvement in the design, conduct, interpretation and publication of this study. The authors have no conflicts of interest to disclose that are relevant for this manuscript. Non-financial disclosure: nothing relevant to disclose.
RkJQdWJsaXNoZXIy MjY0ODMw